Erbitux 5 mg/ml Injection

Erbitux 5 mg/ml Injection belongs to a class of monoclonal antibodies. It is used with or without radiation therapy to treat various cancer conditions, such as metastatic cancer of the large intestine and squamous cell cancer (a certain type of head and neck cancer). Cancer is a genetic change in which the body's cells divide uncontrollably and spread into surrounding tissues.

Erbitux 5 mg/ml Injection contains Cetuximab, which works by slowing or stopping the growth of cancer cells. As a result, it prevents the cancer from spreading.

Erbitux 5 mg/ml Injection will be administered by a qualified healthcare professional who is experienced in the administration of chemotherapeutic agents. The most common side effects are inflammation of the lining of the intestine, mouth, and nose, nose bleeding, headache, tiredness, irritation and redness of the eye, diarrhoea, feeling sick, vomiting, loss of appetite, and weight loss. Talk to your doctor if any of these side effects persist or worsen.

It is recommended not to use if you are allergic to any ingredient in Erbitux 5 mg/ml Injection . Erbitux 5 mg/ml Injection may cause foetal harm when administered to a pregnant woman. It is critical not to become pregnant while undergoing therapy and for several months after the treatment. Before beginning treatment, discuss effective contraception with your healthcare professional. Inform them immediately if you or your partner becomes pregnant while undergoing therapy. Do not breastfeed your baby while on treatment with Cetuximab and for two months after the last dose. Alcohol should be avoided during treatment with this medicine. Drive only if you are alert, as the Erbitux 5 mg/ml Injection may cause you to feel sick or tired.

If you have head and neck cancer and are treated with radiation therapy with cetuximab, you may be at an elevated risk of cardiopulmonary arrest (when the heart stops beating and respiration stops) and sudden death during or after treatment. Inform your doctor if you have or have ever had coronary artery disease (a condition in which the blood vessels of the heart narrow or become clogged by fat or cholesterol deposits); heart failure (a condition in which the heart is unable to pump enough blood to the rest of the body); irregular heartbeat; other heart disease; or lower than normal levels of magnesium, potassium, or calcium in your blood.

Erbitux 5 mg/ml Injection is a monoclonal antibody. It is used alone or in combination with other anticancer medications to treat various cancer diseases, including metastatic cancer of the large intestine and squamous cell cancer (a form of head and neck cancer). Cetuximab is present in Erbitux 5 mg/ml Injection and works by slowing or preventing the growth of cancer cells. As a result, it inhibits the cancer from spreading.

Before taking Erbitux 5 mg/ml Injection , inform your doctor about your medical history and ongoing therapies to rule out potential adverse effects or interactions. It's crucial to take your medication as directed. The dosage of this medicine is based on your condition. Your doctor may adjust your dose during therapy based on the treatment results. Consult a doctor immediately if you suffer any symptoms, especially if you also have a cough or fever, such as the onset or worsening of breathing problems. If therapy needs to be stopped, your doctor will make that decision. Erbitux 5 mg/ml Injection is recommended not to be used in pregnant women or nursing mothers; if you become pregnant while on treatment with Cetuximab, tell your doctor right away.

Do not skip any scheduled doctor or lab appointments.